Inventor · disambiguated record
Peter Armstrong Thompson
Also filed as: THOMPSON PETER · THOMPSON PETER A · THOMPSON PETER ARMSTRONG
10 granted patents·42 pending applications·208 citations·filing 2005–2021
89Inventor score
Files withEMERGENT PRODUCT DEV SEATTLE11SILVERBACK THERAPEUTICS INC9TRUBION PHARMACEUTICALS INC7OPI VI IP HOLDCO LLC5THOMPSON PETER ARMSTRONG4
Top patents by PatentIndex Score
52 records- 0195US8409577B2Single chain multivalent binding proteins with effector functionTHOMPSON PETER ARMSTRONG·Filed 2007·Granted Apr 2, 2013·140 cites·17 claims
- 0288US7846434B2Materials and methods for improved immunoglycoproteinsTRUBION PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·14 cites·17 claims
- 0387US9493564B2CD86 antagonist multi-target binding proteinsTHOMPSON PETER ARMSTRONG·Filed 2009·Granted Nov 15, 2016·12 cites·33 claims
- 0486US10988543B2Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumorOPI VI—IP HOLDCO LLC·Filed 2016·Granted Apr 27, 2021·6 cites·17 claims
- 0586US9101609B2CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereofTAN PHILIP·Filed 2009·Granted Aug 11, 2015·13 cites·5 claims
- 0685US8632774B2Antagonists of IL-6MISHER LYNDA·Filed 2009·Granted Jan 21, 2014·20 cites·12 claims
- 0774US2020354447A1Single-chain multivalent binding proteins with effector functionAPTEVO RES & DEVELOPMENT LLC·Filed 2019·Application pending·0 cites
- 0869US8383106B2Materials and methods for improved immunoglycoproteinsEMERGENT PRODUCT DEV SEATTLE·Filed 2010·Granted Feb 26, 2013·2 cites·11 claims
- 0967US10307481B2CD37 immunotherapeutics and uses thereofGROSMAIRE LAURA S·Filed 2006·Granted Jun 4, 2019·1 cites·14 claims
- 1065US11541126B1Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·0 cites·30 claims
- 1164US2009214539A1B-cell reduction using cd37-specific and cd20-specific binding moleculesTRUBION PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1263US2018118823A1Single-chain multivalent binding proteins with effector functionAPTEVO RES & DEVELOPMENT LLC·Filed 2017·Application pending·0 cites
- 1363US2023062712A1Anti-asgr1 antibody conjugates and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1462US2009196870A1Binding constructs and methods for use thereofTRUBION PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 1561US2013336977A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 1661US2014127203A1Single-chain multivalent binding proteins effector functionTHOMPSON PETER ARMSTRONG·Filed 2013·Application pending·0 cites
- 1761US2014141022A1Single-chain multivalent binding proteins with effector functionTHOMPSON PETER ARMSTRONG·Filed 2013·Application pending·0 cites
- 1861US2023081264A1Compositions and methods for microglia replacement therapyGLIA BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1960US2014154250A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 2060US2021139604A1Compositions of antibody construct-agonist conjugates and methods of use thereofOPI VI IP HOLDCO LLC·Filed 2020·Application pending·0 cites
- 2160US2014154252A1Single-chain multivalent binding proteins with effector functionEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 2259US2011217302A1TCR Complex ImmunotherapeuticsEMERGENT PRODUCT DEV SEATTLE·Filed 2009·Application pending·0 cites
- 2359US2019290755A1B-cell reduction using cd37-specific and cd20-specific binding moleculesAPTEVO RES & DEVELOPMENT LLC·Filed 2018·Application pending·0 cites
- 2458US2009258005A1Therapeutic compositions and methodsTRUBION PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2557US2021301028A1Composition and methods for anti-tnfr2 antibodiesOPI VI IP HOLDCO LLC·Filed 2021·Application pending·0 cites
- 2656US10143748B2B-cell reduction using CD37-specific and CD20-specific binding moleculesEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Granted Dec 4, 2018·0 cites·8 claims
- 2754US2010150948A1Materials and methods for improved immunoglycoproteinsTRUBION PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2853US2014086903A1Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereofTAN PHILIP·Filed 2013·Application pending·0 cites
- 2953US2013195850A1Cd3 immunotherapeutics and uses thereofTAN PHILIP·Filed 2012·Application pending·0 cites
- 3052US2017298139A1Compositions of antibody construct-agonist conjugates and methods of use thereofOPI VI - IP HOLDCO LLC·Filed 2017·Application pending·0 cites
- 3150US2013189261A1TCR Complex ImmunotherapeuticsEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 3250US2020113912A1Methods and Compositions for the Treatment of Disease with Immune Stimulatory ConjugatesSILVERBACK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3350US2021130473A1TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOFSILVERBACK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3450US2021154317A1Compositions and methods for the treatment of viral infectionsSILVERBACK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3550US2010135900A1Cd37 immunotherapeutic combination therapies and uses thereofTRUBION PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3650US2011158995A1Multi-Specific Binding Proteins Targeting B Cell DisordersRENAULT SA·Filed 2009·Application pending·0 cites
- 3749US2011177070A1TGF-Beta Antagonist Multi-Target Binding ProteinsEMERGENT PRODUCT DEV SEATLLE LLC·Filed 2009·Application pending·0 cites
- 3849US2009304590A1Therapeutic compositions and methodsWYETH CORP·Filed 2008·Application pending·0 cites
- 3949US2017158772A1Compositions of antibody construct - agonist conjugates and methods of use thereofOPI VI - IP HOLDCO LLC·Filed 2016·Application pending·0 cites
- 4049US2021115109A1Conjugates and methods of use thereof for selective delivery of immune-modulatory agentsSILVERBACK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4148US2013280240A1Materials and Methods for Improved ImmunoglycoproteinsEMERGENT PRODUCT DEV SEATTLE·Filed 2013·Application pending·0 cites
- 4248US2013323233A1Materials and methods for improved immunoglycoproteinsEMERGENT PRODUCT DEV SEATTLE·Filed 2012·Application pending·0 cites
- 4347US2012121505A1Therapeutic compositions and methodsGILL DAVINDER SINGH·Filed 2012·Application pending·0 cites
- 4447US2011152173A1TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINSEMERGENT PRODUCT DEV SEATTLE·Filed 2009·Application pending·0 cites
- 4546US2020199242A1Construct-peptide compositions and methods of use thereofSILVERBACK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4644US2017008960A1TCR Complex ImmunotherapeuticsEMERGENT PRODUCT DEV SEATTLE·Filed 2016·Application pending·0 cites
- 4744US2008227958A1Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functionsTRUBION PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 4843US2019135923A1Compositions and treatment methods for cancer immunotherapyBIOGRAPH 55 INC·Filed 2019·Application pending·0 cites
- 4943US2020199247A1Antibody conjugates of immune-modulatory compounds and uses thereofSILVERBACK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5041US2019336615A1Tumor targeting conjugates and methods of use thereofSILVERBACK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peter Armstrong Thompson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →